Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.

Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, Buffet J, Pointreau Y, Sire C, Tuchais C, Babin E, Coutte A, Rolland F, Kaminsky MC, Alfonsi M, Lapeyre M, Saliou M, Lafond C, Jadaud E, Gery B, Zawadi A, Tourani JM, Khoury C, Henry AR, Hasbini A, Guichard F, Borel C, Meert N, Guillet P, Calais MH, Garaud P, Bourhis J.

J Clin Oncol. 2018 Jul 17:JCO2017762591. doi: 10.1200/JCO.2017.76.2591. [Epub ahead of print]

PMID:
30016178
2.

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.

Tao Y, Auperin A, Sire C, Martin L, Khoury C, Maingon P, Bardet E, Kaminsky MC, Lapeyre M, Chatellier T, Alfonsi M, Pointreau Y, Jadaud E, Géry B, Zawadi A, Tourani JM, Laguerre B, Coutte A, Racadot S, Hasbini A, Malaurie E, Borel C, Meert N, Cornely A, Ollivier N, Casiraghi O, Sun XS, Bourhis J.

J Clin Oncol. 2018 Jun 7:JCO2017762518. doi: 10.1200/JCO.2017.76.2518. [Epub ahead of print]

PMID:
29878867
3.

Practical tool for sampling and fast analysis of large cocaine seizures.

Eliaerts J, Meert N, Van Durme F, Samyn N, De Wael K, Dardenne P.

Drug Test Anal. 2018 Jun;10(6):1039-1042. doi: 10.1002/dta.2364. Epub 2018 Mar 23.

PMID:
29396917
4.

Rapid classification and quantification of cocaine in seized powders with ATR-FTIR and chemometrics.

Eliaerts J, Dardenne P, Meert N, Van Durme F, Samyn N, Janssens K, De Wael K.

Drug Test Anal. 2017 Oct;9(10):1480-1489. doi: 10.1002/dta.2149. Epub 2017 Mar 31.

PMID:
27977911
5.

Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.

Mardjuadi FI, Carrasco J, Coche JC, Sempoux C, Jouret-Mourin A, Scalliet P, Goeminne JC, Daisne JF, Delaunoit T, Vuylsteke P, Humblet Y, Meert N, van den Eynde M, Moxhon A, Haustermans K, Canon JL, Machiels JP.

Target Oncol. 2015 Sep;10(3):375-83. doi: 10.1007/s11523-014-0342-9. Epub 2014 Oct 11.

PMID:
25304881
6.

Cervical node of unknown primary: patterns of care and factors influencing the choice of clinical target volumes.

Troussier I, Bensadoun RJ, Chamorey E, Lapeyre M, Baujat B, Leysalle A, Sun XS, Pointreau Y, Calugaru V, Pan Q, Ovidiu V, Schultz P, Malard O, Bujor L, Morinière S, Chamois J, Coutte A, Michel X, Huguet F, Fouillet B, Roth V, Vernat SS, Meert N, Gallocher O, Drouet F, Lang P, Thariat J.

Oral Oncol. 2014 May;50(5):e25-6. doi: 10.1016/j.oraloncology.2014.02.010. Epub 2014 Mar 11. No abstract available.

PMID:
24630259
7.

Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications.

Meert N, Schepers E, Glorieux G, Van Landschoot M, Goeman JL, Waterloos MA, Dhondt A, Van der Eycken J, Vanholder R.

Nephrol Dial Transplant. 2012 Jun;27(6):2388-96. doi: 10.1093/ndt/gfr672. Epub 2011 Dec 13.

PMID:
22167586
8.

Factors determining yield and quality of illicit indoor cannabis (Cannabis spp.) production.

Vanhove W, Van Damme P, Meert N.

Forensic Sci Int. 2011 Oct 10;212(1-3):158-63. doi: 10.1016/j.forsciint.2011.06.006. Epub 2011 Jul 7.

PMID:
21737218
9.

Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities.

Meert N, Eloot S, Schepers E, Lemke HD, Dhondt A, Glorieux G, Van Landschoot M, Waterloos MA, Vanholder R.

Nephrol Dial Transplant. 2011 Aug;26(8):2624-30. doi: 10.1093/ndt/gfq803. Epub 2011 Feb 10.

PMID:
21310741
10.

Prospective evaluation of the change of predialysis protein-bound uremic solute concentration with postdilution online hemodiafiltration.

Meert N, Waterloos MA, Van Landschoot M, Dhondt A, Ledebo I, Glorieux G, Goeman J, Van der Eycken J, Vanholder R.

Artif Organs. 2010 Jul;34(7):580-5. doi: 10.1111/j.1525-1594.2010.01005.x. Epub 2010 Jun 10.

PMID:
20545662
11.

Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.

Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, Vanholder R, Meijers B, Meert N, Fassbender WJ, Floege J, Jahnen-Dechent W, Ketteler M.

Nephrol Dial Transplant. 2010 Aug;25(8):2672-9. doi: 10.1093/ndt/gfq053. Epub 2010 Feb 18.

PMID:
20172849
12.

Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease.

Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, Temmar M, Choukroun G, Vanholder R, Massy ZA; European Uraemic Toxin Work Group (EUTox).

Nephrol Dial Transplant. 2010 Apr;25(4):1183-91. doi: 10.1093/ndt/gfp592. Epub 2009 Nov 13.

PMID:
19914995
13.

Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.

Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox).

Clin J Am Soc Nephrol. 2009 Oct;4(10):1551-8. doi: 10.2215/CJN.03980609. Epub 2009 Aug 20.

14.

A practice survey of the evolution of rectal cancer management: a Belgian Federal College of radiotherapy study.

Magné N, Daisne JF, Moretti L, Berben D, Meert N, Alen R, Bral S, Cleef AV, Haustermans K, Houtte PV, Scalliet P.

Bull Cancer. 2009 Jul-Aug;96(7):E45-51. doi: 10.1684/bdc.2009.0914.

15.

Evolution of protein-bound uraemic solutes during predilution haemofiltration.

Meert N, Beerenhout C, Schepers E, Glorieux G, Kooman J, Vanholder R.

J Nephrol. 2009 May-Jun;22(3):352-7.

PMID:
19557711
16.

Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes?

Vanholder R, Meert N, Van Biesen W, Meyer T, Hostetter T, Dhondt A, Eloot S.

Nat Clin Pract Nephrol. 2009 Mar;5(3):130-1. doi: 10.1038/ncpneph1023. Epub 2008 Dec 23. No abstract available.

PMID:
19107105
17.

Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients.

von Zur Muhlen C, Schiffer E, Zuerbig P, Kellmann M, Brasse M, Meert N, Vanholder RC, Dominiczak AF, Chen YC, Mischak H, Bode C, Peter K.

J Proteome Res. 2009 Jan;8(1):335-45. doi: 10.1021/pr800615t.

PMID:
19053529
18.

Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial.

Meert N, Eloot S, Waterloos MA, Van Landschoot M, Dhondt A, Glorieux G, Ledebo I, Vanholder R.

Nephrol Dial Transplant. 2009 Feb;24(2):562-70. doi: 10.1093/ndt/gfn522. Epub 2008 Sep 22.

PMID:
18809977
19.

From uremic toxin retention to removal by convection: do we know enough?

Vanholder R, Meert N, Schepers E, Glorieux G.

Contrib Nephrol. 2008;161:125-131. doi: 10.1159/000130657. Review.

PMID:
18451668
20.

Uremic toxins: do we know enough to explain uremia?

Vanholder R, Meert N, Schepers E, Glorieux G.

Blood Purif. 2008;26(1):77-81. doi: 10.1159/000110570. Epub 2008 Jan 10. Review.

PMID:
18182802
21.

Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro--towards a standardized approach for research on uraemia.

Cohen G, Glorieux G, Thornalley P, Schepers E, Meert N, Jankowski J, Jankowski V, Argiles A, Anderstam B, Brunet P, Cerini C, Dou L, Deppisch R, Marescau B, Massy Z, Perna A, Raupachova J, Rodriguez M, Stegmayr B, Vanholder R, Hörl WH; European Uremic Toxin Work Group (EUTox).

Nephrol Dial Transplant. 2007 Dec;22(12):3381-90. Epub 2007 Aug 27. Review. No abstract available. Erratum in: Nephrol Dial Transplant. 2008 Feb;23(2):780.

PMID:
17724037
22.

Inconsistency of reported uremic toxin concentrations.

Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, Drüeke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R.

Artif Organs. 2007 Aug;31(8):600-11. Review.

PMID:
17651115
23.

Review on uraemic solutes II--variability in reported concentrations: causes and consequences.

Vanholder R, Meert N, Schepers E, Glorieux G, Argiles A, Brunet P, Cohen G, Drüeke T, Mischak H, Spasovski G, Massy Z, Jankowski J; European Uremic Toxin Work Group (EUTox).

Nephrol Dial Transplant. 2007 Nov;22(11):3115-21. Epub 2007 Jun 5. Review.

PMID:
17550927
24.

Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors.

Valli A, Suliman ME, Meert N, Vanholder R, Lindholm B, Stenvinkel P, Watanabe M, Barany P, Alvestrand A, Anderstam B.

Clin Chim Acta. 2007 Apr;379(1-2):87-94. Epub 2007 Jan 16.

PMID:
17292872
25.

P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production.

Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R.

Nephrol Dial Transplant. 2007 Feb;22(2):592-6. Epub 2006 Oct 13.

PMID:
17040995
26.

What is uremia? Retention versus oxidation.

Vanholder R, Schepers E, Meert N, Lameire N.

Blood Purif. 2006;24(1):33-8. Review.

27.

Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice.

Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R, Ketteler M, Meert N, Maizel J, Nikolov IG, Vanholder R, Lacour B, Drüeke TB, Massy ZA.

Circulation. 2005 Nov 1;112(18):2875-82.

PMID:
16267260
28.

Pre-dilution on-line haemofiltration vs low-flux haemodialysis: a randomized prospective study.

Beerenhout CH, Luik AJ, Jeuken-Mertens SG, Bekers O, Menheere P, Hover L, Klaassen L, van der Sande FM, Cheriex EC, Meert N, Leunissen KM, Kooman JP.

Nephrol Dial Transplant. 2005 Jun;20(6):1155-63. Epub 2005 Mar 22.

PMID:
15784639
29.

Proteomics: a novel tool to unravel the patho-physiology of uraemia.

Weissinger EM, Kaiser T, Meert N, De Smet R, Walden M, Mischak H, Vanholder RC.

Nephrol Dial Transplant. 2004 Dec;19(12):3068-77. Epub 2004 Oct 19.

PMID:
15494356

Supplemental Content

Support Center